Colorectal cancer chemotherapy: Irinotecan

Seminars in Oncology

Volumn 27, Issue 5 SUPPL. 10, 2000, Pages 138-143

  Rougier, P ^a   Mitry, E ^a  

^a HÔPITAL AMBROISE PARÉ   (France)

Author keywords

[No Author keywords available]

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; 9 AMINOCAMPTOTHECIN; 9 NITROCAMPTOTHECIN; CAPECITABINE; DNA TOPOISOMERASE INHIBITOR; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IRINOTECAN; OXALIPLATIN; THYMIDYLATE SYNTHASE INHIBITOR; TOMUDEX; TOPOTECAN;

CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; CONFERENCE PAPER; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TRANSFORMATION; HUMAN; PRIORITY JOURNAL; QUALITY OF LIFE; SIDE EFFECT; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CLINICAL TRIALS; COLORECTAL NEOPLASMS; DNA TOPOISOMERASES, TYPE I; ENZYME INHIBITORS; HUMAN;

EID: 0033790098     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (42)

1. The chemotherapy of colon cancer can no longer be ignored
2. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer
3. CPT-11 in gastrointestinal cancer
4. Topoisomerase I inhibitors: Review and update
5. Comparison of topoisomerase I inhibition. DNA damage, and cytotoxicity of camptothecin derivatives presently in clinical trials
6. Rational design of irinotecan administration based on preclinical models
7. Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11
8. Metabolism and pharmacokinetics of the camptothecin analogue CPT-11 in the mouse
9. Role of carboxylesterase on metabolism of camptothecin analogues (CPT-11) in non-small cell lung cancer cell line PC-7 cells
10. Metabolic activation of CPT-11, 7-ethyl-10-[4-(piperidino)- 1-piperidino] carboxyloxycamptothecin: A novel anti-tumor agent, by carboxylesterase
11. Phase I pharmacokinetic (PK) study of irinotecan (CPT-11) in cancer patients (pts) with hepatic dysfunction
12. Setting a new standard - Irinotecan (Campto) in the second-line treatment of colorectal cancer: Final results of two phase III studies and implications for clinical practice
13. Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy
14. Clinical benefit of irinotecan (CPT-11) in metastatic colorectal cancer resistant to 5-FU
15. Phase II trial of irinotecan in patients with metastatic colorectal cancer
16. Tumor response and stabilization rates are worthwhile surrogate endpoints in metastatic colorectal cancer: Analysis of data in 455 5-FU resistant patients treated with CPT-11
17. Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer
18. Randomized trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer
19. Randomized trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer
20. Final results of randomized trial comparing Tomudex (raltitrexed) with 5-fluorouracil plus leucovorin in advanced colorectal cancer
21. Advanced colorectal cancer: Results from the latest ralititrexed (Tomudex) comparative study
22. Clinical efficacy of Tomudex (raltitrexed) in advanced colorectal cancer
23. Open label dose finding phase I study of irinotecan hydrochloride and raltitrexed in patients with advanced gastrointestinal tract adenocarcinoma
24. Oxaliplatin effects on naked and intracellular DNA
25. Oxaliplatin (L-OHP) as first-line chemotherapy in metastatic colorectal cancer (MCRC) patients: Preliminary activity/toxicity report
26. Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinomas who were resistant to previous treatment with fluoropyrimidines
27. Oxaliplatin (LOHP) and cisplatin (CDDP) in combination with 5FU, specific thymidylate synthase (TS) inhibitors (AG337, ZD1694), and topoisomerase I (topo-I) inhibitors (SN38, CPT-11) in human colonic, ovarian and breast cancers
28. CPT-11/oxaliplatin (L-OHP) every two weeks: A phase I study in patients with advanced digestive tumors
29. CPT-11/oxaliplatin (L-OHP): Thymidylate synthase (TS) independent combination with efficacy in 5-FU refractory colorectal cancer (CRC) patients (PTS)
30. Oxaliplatin (L-OHP) and irinotecan (CPT11) phase I/II studies: Results in 5 FU refractory (FR) colorectal cancer (CRC) patients (pts)
31. Phase II study of CPT-11, a new camptothecin derivative, in metastatic colorectal cancer
32. Irinotecan is an active agent in untreated patients with metastatic colorectal cancer
33. Phase II trial of irinotecan in patients with metastatic colorectal carcinoma
34. Weekly irinotecan (CPT-11), leucovorin (LV), and fluorouracil (FU) is superior to daily x 5 LV/FU in patients (pts) with previously untreated metastatic colorectal cancer (CRC)
35. The advanced colorectal meta-analysis project. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: Evidence in terms of response rate
36. Phase I/II study of escalating dose of CPT-11 in combination with LV5FU2 ('De Gramont' regimen) every two weeks in the treatment of colorectal cancer (CRC) after 5-FU failure
37. Phase I/II study of CPT-11 in combination with LV2FU5 (De Gramont-regimen) every 2 weeks for the treatment of colorectal cancer (CRC) after 5FU failure
38. Phase I study of weekly schedule of irinotecan, high dose leucovorin and infusional fluorouracil as first-line chemotherapy in patients with advanced metastatic colorectal cancer
39. A phase II study of irinotecan alternated with five day bolus of 5-fluorouracil and leucovorin in first-line chemotherapy of metastatic colorectal cancer
40. A phase II multicenter trial of alternating cycles of irinotecan (CPT-11) and 5-FU/LV in patients with previously untreated metastatic colorectal cancer (CRC)
41. A randomized phase III trial comparing irinotecan (IRI) to 5FU/folinic acid (FA) to the same schedule of 5FU/FA in patients (pts) with metastatic colorectal cancer as front line chemotherapy (CT)
42. Weekly irinotecan (CPT11), leucovorin (LV), and fluorouracil (FU) is superior to daily x 5 LV/FU in patients (pts) with previously untreated metastatic colorectal cancer (CRC)